The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global bifurcation lesions market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026.
A bifurcation lesion refers to the narrowing of the coronary artery adjacent to the origin of a significant side branch (SB). It is prone to develop atherosclerotic plaque due to turbulent blood flow and high shear stress. It is treated using techniques like analysis, procedure duration, X-ray exposure, and long-term follow-up. Moreover, three-dimensional (3D) angiography and multi-slice computed tomography are utilized for measuring the bifurcation angles. With the advances in devices, imaging, adjunctive pharmacotherapy, and vascular access, the management of complex cases of bifurcation lesions is becoming possible worldwide.
A significant rise in the occurrence of coronary artery disease (CAD) is increasing the risk of developing bifurcation lesions. This represents one of the key factors bolstering the market growth. Besides this, the approval of innovative devices, increasing insurance coverage, and improving imaging modalities are also strengthening the market growth. Moreover, the rising geriatric population, which is more likely to develop medical ailments, along with supportive initiatives undertaken by governments of various countries for reimbursement, is supporting the market growth. The increasing medical tourism, the escalating demand for minimally invasive (MI) procedures and the improving healthcare infrastructure are some of the other factors contributing to the growth of the market. Apart from this, the ongoing research on novel treatment techniques is driving the market. For instance, researchers are studying the effectiveness of the Szabo 2-stent technique for complex bifurcations lesions with high compromise risk or fatal consequences of SB occlusion. Furthermore, a wide range of clinical trials on stents and balloons, in confluence with the increasing number of skilled healthcare professionals, is anticipated to decrease risks associated with bifurcation lesions treatment and influence the market positively.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bifurcation lesions market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, types and application.
Breakup by Types:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.) and Terumo Corporation.
|Base Year of the Analysis||2020|
|Segment Coverage||Types, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Boston Scientific Corporation, Cardinal Health, Medtronic plc, Spectranetics (Koninklijke Philips N.V.) and Terumo Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at